By offering cutting-edge resources along with proven therapeutic techniques, we aim to help those battling addiction reclaim their lives
Both semaglutide and tirzepatide are administered as weekly subcutaneous injections
In this post-analysis of 327 participants, the average weight loss after 68 weeks was 17.3% with semaglutide and 2% with placebo
The SURMOUNT-5 data on waist circumference is also clinically meaningful: research has shown that each 5-centimeter increase in waist circumference corresponds to a 7 to 9 percent increase in mortality risk, making the 5.4-centimeter additional reduction with tirzepatide a potentially significant benefit.1 That said, semaglutide remains highly effective and is still the right choice for many patients, depending on insurance coverage, cost, tolerance, and individual response
And then their insurance stops covering it, or it gets too costly for them
These sessions enabled healthcare providers to monitor weight loss, address challenges faced by patients, and celebrate successes, reinforcing the goal of long-term weight maintenance and compliance